Key facts
- This page summarizes Chairman Michael J. Farrell's Form 4 filing for ZIMMER BIOMET HOLDINGS, INC. (ZBH).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 May 2022, 17:33.
Chairman Michael J. Farrell - 13 May 2022 Form 4 Insider Report for ZIMMER BIOMET HOLDINGS, INC. (ZBH)
- Reporting relationship
- Director
- Issuer ticker
- ZBH
- Reported as of
- 13 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 May 2022, 17:33:49 UTC
- Prior SEC filing
- 19 Apr 2022
- Next SEC filing
- 17 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew R. St. Louis, Attorney-in-Fact for Michael J. Farrell (power of attorney previously filed)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chairman Michael J. Farrell filed Form 4 for ZIMMER BIOMET HOLDINGS, INC. (ZBH) on 17 May 2022.
Change
- Previous filing in this sequence was filed on 19 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBH
transaction
Derivative
Phantom Stock Units
Award
- Transaction value
- $0
- Shares
- +500
- Change %
- +4.8%
- Price
- $0.000000
- Shares after
- 10,850
- Date
- 13 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500
- Exercise price
- $115.13
- Footnotes
- F1, F2, F3, F4
ZBH
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +1,129
- Change %
- +15%
- Price
- $0.000000
- Shares after
- 8,812
- Date
- 13 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,129
- Exercise price
- Footnotes
- F2, F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. (the "Company") Deferred Compensation Plan for Non-Employee Directors.
Footnote F2
The Conversion or Exercise Price of Derivative Security is 1-for-1.
Footnote F3
These units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
Footnote F4
Includes 19.183 phantom stock units accrued on April 29, 2022 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Footnote F5
The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date.
Footnote F6
Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Also reflects the adjustments that occurred as of March 1, 2022 in connection with the spinoff of ZimVie Inc. In connection with the spinoff, each then outstanding Restricted Stock Unit was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit.